Heart Care Centers of Florida is the first practice on the East Coast to install dedicated cardiovascular CT scanner Caesarea, Israel – Feb. 10, 2024 – Arineta, a leader in advancing cardiovascular imaging solutions, shares the installation of its SpotLight™ cardiac CT scanner at Heart Care Centers of Florida (HCCF) […]
Coronary/Structural Heart
Catheter Precision to Attend and Participate in the 13th Internation Symposium on Left Atrial Appendage
FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas.
Centers Health Care Honored with American Heart Association Achievement Award for Cardiovascular Care Excellence
Centers Celebrates Target: BP™ During Heart Month; Hosts Jumping Jacks Challenge Across Facilities BRONX, N.Y., Feb. 5, 2025 /PRNewswire/ — Centers Health Care, the largest and most complete post-acute health care continuum in the Northeast that touches one million lives each year with…
E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney diseases, today announced that it has dosed its first patient in a Phase 2 clinical trial of Modified Atrial Natriuretic Peptide (MANP) for the treatment of Resistant Hypertension (BOLD-HTN). MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Clinic entered into a worldwide exclusive license agreement for the development of MANP in cardiovascular and metabolic indications in 2021. With the support of $36 million in grants and seed-stage private investment, MANP has demonstrated a strong safety profile in multiple Phase 1 studies of participants with hypertension, resistant hypertension, and hypertension with comorbid cardiometabolic syndrome. Jesse Crowne, Chief Executive Officer of E-Star Biotech commented, “We are thrilled to have now dosed the first patient in our phase 2 study of MANP, the BOLD-HTN Study, which is a randomized, placebo-controlled, double-blind, multi-center Phase 2 study to evaluate the safety and efficacy of MANP in participants with Resistant Hypertension. This is the first step towards fully enrolling the study later this year, and finding new treatment pathways for patients with resistant hypertension.” An estimated 1.28 billion adults aged 30-79 years old suffer from hypertension worldwide. While scores of drugs are available to treat hypertension, only 1 in 5 adults (approximately 21%) with hypertension gain control of their condition. Hypertension remains a leading driver of premature death in both developed and developing countries. E-Star is dedicated to bringing the remaining 79% of hypertension patients under control and reducing the burden of premature death. About E-Star BioTech, LLC E-Star is developing a platform of Natriuretic Peptides for the treatment of metabolic syndrome. The Company’s lead asset, MANP, is currently being investigated in a Phase 2 clinical trial. To learn more, please visit: https://www.e-star.bio/. About Mayo ClinicMayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. Contact: LR AdvisorsJason Assad678-570-6791
BrightHeart Unveils Breakthrough AI Results at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, Revolutionizing Prenatal Care
PARIS–(BUSINESS WIRE)–BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on January 30th at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, held in Aurora, Colorado. As the first major unveiling of the […]
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study January 30, 2025 06:45 AM Eastern Standard Time RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced […]
AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with […]
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
Smartphone App Predicts Cardiovascular Damage from Vaping
PASADENA, Calif., Jan. 28, 2025 /PRNewswire/ — Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, provides crucial insights into predicting the long-term risk for cardiovascular damage from e-cigarettes…
Ncardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision Medicine
LEIDEN, The Netherlands–(BUSINESS WIRE)–Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery. “With Ncyte® Heart in a Box, we are empowering researchers to […]